Lipo-C Fat Blaster vs Lemon Bottle
Lipo-C Fat Blaster is a compounded lipotropic injectable whose typical constituents are methionine, inositol, choline, L-carnitine and vitamin B12. Lemon Bottle is a branded injectable lipolytic, and the research entry for it in this library records that the branded formulation was not identified in any peer-reviewed clinical or mechanistic study; the evidence that describes its category is the literature on deoxycholic acid, a synthetic bile salt approved for submental fat reduction, and on compounded phosphatidylcholine with sodium deoxycholate. Marketed descriptions of the branded product are not consistent with one another, with some vendor material listing a riboflavin-based composition rather than a bile-salt one, and none of those descriptions has been verified in an indexed publication. No study has administered the lipotropic blend and none has tested the branded lipolytic, so no direct comparison exists. What the literature does contain is a series of experiments that injected phosphatidylcholine and sodium deoxycholate, separately and combined, and asked which component was responsible for the loss of fat.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered the methionine, inositol, choline, carnitine and vitamin B12 blend to anything, and no published study has tested the branded lipolytic, so nothing has compared them. Searches of PubMed and Europe PMC returned no trial, case report or mechanistic study of either product, and no study in which a lipotropic injection was set against an injectable lipolytic within one design. The papers listed below engage the two mechanistic classes rather than the two products: each administered a choline-containing phospholipid alongside sodium deoxycholate, or reviewed that body of work. Their consistent result is that the detergent, not the phospholipid, does the damage. Deoxycholate alone reduced adipocyte viability in vitro at low concentrations while neither agent induced an enzymatic lipolytic pathway; in mice, injected phosphatidylcholine reduced tissue mass while deoxycholic acid reduced DNA content and drove inflammation; and in a randomised double-blind trial in submental fat, adding phosphatidylcholine to deoxycholate changed neither efficacy nor the adverse-event profile. None of that work tested the nutrients used in a lipotropic injection, which have been studied almost entirely as oral or dietary exposures.
The 11 publications that cover both
- 01In vitro2004
Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution
Rotunda AM, Suzuki H, Moy RL, Kolodney MS · Dermatologic Surgery · cell-lysis assays and exposure of porcine and human tissue to the separate components of a phosphatidylcholine-deoxycholate formulation
The cell-lysing activity of the injectable formulation was attributed to sodium deoxycholate rather than to the phosphatidylcholine it solubilised. The detergent lysed cells non-selectively, which the authors identified as a major feature of the preparation used for localised fat dissolution.
- 02Animal in vivo2008
Tissue-toxic effects of phosphatidylcholine/deoxycholate after subcutaneous injection for fat dissolution in rats and a human volunteer
Schuller-Petrovic S, Wolkart G, Hofler G, et al. · Dermatologic Surgery · 30-day chronic study in rats given three subcutaneous abdominal injections of phosphatidylcholine/deoxycholate, with deoxycholate tested separately for comparison, plus one human volunteer treated before elective liposuction
The combined formulation reduced membrane integrity and cell viability in proportion to the volume injected and produced fibroplasia, band-like fibrosis and partial muscle loss, with widespread fat necrosis, fat cyst formation and necrosis of small vessel walls at the largest volume. Deoxycholate tested alone exerted membrane and histological effects similar to those of the combination, and biopsies from the human volunteer showed panniculitis, fat cysts and vessel necrosis.
- 03In vitro2009
In vitro studies investigating the effect of subcutaneous phosphatidylcholine injections in the 3T3-L1 adipocyte model: lipolysis or lipid dissolution?
Klein SM, Schreml S, Nerlich M, Prantl L · Plastic and Reconstructive Surgery · 3T3-L1 adipocytes exposed to isolated phosphatidylcholine, isolated deoxycholate and the two combined, with membrane-integrity microscopy, a glycerol-release lipolysis assay and viability assays
Deoxycholate significantly reduced cell viability even at low concentrations, and the combination reduced viability significantly at low exposure and highly significantly at high exposure. Neither phosphatidylcholine nor deoxycholate induced a lipolytic pathway, and the loss of viability was attributed to changes in cell-membrane integrity rather than to enzymatic fat breakdown.
- 04Human clinical2009
Randomized double-blind clinical trial of subcutaneously injected deoxycholate versus a phosphatidylcholine-deoxycholate combination for the reduction of submental fat
Rotunda AM, Weiss SR, Rivkin LS · Dermatologic Surgery · single-centre randomised double-blind exploratory trial, 42 adults enrolled and 32 assessed photographically, deoxycholate compared with a phosphatidylcholine-deoxycholate mixture in submental fat over up to five treatment visits at four-week intervals
Both arms produced only modest photographic change in the submental profile, with mean improvement of 0.8 for deoxycholate and 0.6 for the combination on a four-point scale and a median of 0.5 in both groups. No notable differences were observed between treatments in physical examination, in the incidence, duration or severity of adverse events, or in participants' own assessments, and the authors reported that including phosphatidylcholine conferred no apparent advantage.
- 05Animal in vivo2013
Injection of phosphatidylcholine and deoxycholic acid regulates gene expression of lipolysis-related factors, pro-inflammatory cytokines, and hormones on mouse fat tissue
Won TJ, Nam Y, Lee HS, et al. · Food and Chemical Toxicology · mouse adipose tissue injected separately with phosphatidylcholine or with deoxycholic acid, assessed at seven days for tissue and DNA mass, lipolysis-related and hormone gene expression, cytokine expression and histology
Phosphatidylcholine reduced tissue mass at seven days while deoxycholic acid did not, whereas a fall in DNA mass occurred only in the deoxycholic acid group. Phosphatidylcholine increased hormone-sensitive lipase transcription and induced lipolysis with mild neutrophil infiltration, while deoxycholic acid suppressed the same transcripts, produced no lipolysis and caused heavy neutrophil infiltration. Both reduced adiponectin, leptin and resistin expression and both raised pro-inflammatory cytokine and chemokine expression.
- 06Animal in vivo2014
The role of phosphatidylcholine and deoxycholic acid in inflammation
Chung SJ, Lee CH, Lee HS, et al. · Life Sciences · rodent injection study comparing phosphatidylcholine, deoxycholic acid and the two combined at low and high exposure, with histopathology, myeloperoxidase activity and measurement of interleukin-1 beta, interleukin-6 and prostaglandin E2
Phosphatidylcholine alone induced no inflammatory response at either exposure, while deoxycholic acid produced an intense response that scaled with the amount injected. The combination produced a mild response, less severe than the higher exposure to deoxycholic acid alone. Oedema, neutrophil infiltration and raised cytokine and prostaglandin E2 levels tracked the deoxycholic acid component, and the authors concluded that the adverse effects of the combined formulation were attributable to the bile salt.
- 07Animal in vivo2016
Histopathological and ultra-structural characterization of local neuromuscular damage induced by repeated phosphatidylcholine/deoxycholate injection
El-Gowelli HM, El Sabaa B, Yosry E, El-Saghir H · Experimental and Toxicologic Pathology · 20 female Wistar rats in two groups given percutaneous groin injections of saline or phosphatidylcholine/deoxycholate on four consecutive days, with light and electron microscopy of biopsies taken on the fourth day
Repeated injection of the combined formulation caused neural damage and intense inflammation at the injection site, with skeletal muscle degeneration, necrosis and fibrosis. Electron microscopy showed intraneural fibroblasts, deposition of intraneural collagen fibres and marked myelin degeneration, together with thickening of intraneural blood vessel walls.
- 08Review2022
The Role of Fat Reducing Agents on Adipocyte Death and Adipose Tissue Inflammation
Muskat A, Pirtle M, Kost Y, McLellan BN, Shinoda K · Frontiers in Endocrinology · structured review of 41 articles on phosphatidylcholine, deoxycholic acid and the combined formulation, separated into morphological studies and studies using cell-death and lipolysis measurement techniques
The review recorded that deoxycholic acid was originally included as a solvent for phosphatidylcholine and was later identified as the bioactive component. Most morphological studies reported that all three preparations induced some form of cell death with accompanying inflammation and fibrosis, and that deoxycholic acid alone and in combination was non-selective for adipocytes. The biochemical literature described deoxycholic acid acting as a detergent producing rapid necrosis, and phosphatidylcholine inducing tumour necrosis factor alpha release and apoptosis over a longer interval.
- 09Review2024
Lipolytic agents for submental fat reduction: Review
Park SY, Kim SB, Wan J, Felice F, Yi KH · Skin Research and Technology · narrative review of lipolytic agents used in the submental region, covering aminophylline, hypotonic lipo-dissolution, hyaluronidase-based drainage, choline-containing agents, phosphatidylcholine with deoxycholate, and deoxycholic acid
The review described glycerophosphorylcholine preparations as claiming to activate fat metabolism, noted that phosphatidylcholine combined with deoxycholate lacked cosmetic approval on safety grounds, and recorded that deoxycholic acid held regulatory approval for submental fat reduction while its mechanism remained incompletely understood. It was the only located publication to place a choline-based lipolytic and the bile-salt lipolytic in the same comparative frame.
- 10Systematic review2025
A Systematic Review of Injectable Lipolytic agents for Non-Submental Fat Reduction
Carrion K, Salingaros S, Bernal C, et al. · Plastic and Reconstructive Surgery · systematic review across five databases, 25 included studies covering 3,178 patients treated with deoxycholic acid, phosphatidylcholine and newer formulations at non-submental sites, with ROBINS-I and RoB 2 risk-of-bias assessment
Reductions in localised adiposity were reported in 93.75% of the included studies, but only 37.5% reached statistical significance. Adverse events were generally mild and transient, and patient satisfaction ranged from 57.1% to 86%. The authors concluded that further clinical trials were needed to standardise treatment and to assess long-term efficacy outside the approved submental indication.
- 11Review2026
Injection lipolysis in aesthetic medicine: mechanisms, clinical safety, and clinical applications
Ao Y, Zhou Y · Frontiers in Medicine · narrative review tracing lipolytic agents through literature published between 1943 and 2026, using in vitro data to contrast the effect of deoxycholic acid on adipocytes with its effect on neural tissue
The review reported that deoxycholic acid preferentially disrupted adipocytes with relative tissue selectivity and that the submental fat pad remained the best-documented indication. It recorded skin necrosis and marginal mandibular nerve palsy among the complications associated with poor injection technique, and concluded that systematic safety and efficacy data for injection lipolysis remained limited.
Side by side.
| Lipo-C Fat Blaster | Lemon Bottle | |
|---|---|---|
| Evidence maturity | Clinical | Approved drug |
| Studies cited here | 15 | 17 |
| Published 2023 or later | 11 | 10 |
| Newest paper | 2026 | 2026 |
| Composition and origin | A compounded mixture whose typical constituents are methionine, inositol, choline, L-carnitine and vitamin B12, assembled by compounding pharmacies rather than manufactured as a single authorised medicine. Each constituent is a nutrient with an independent physiological role. | A branded injectable lipolytic. The category is defined in the literature by deoxycholic acid, a synthetic bile salt, and by compounded phosphatidylcholine with sodium deoxycholate. The branded formulation itself has no entry in the indexed literature, and marketed accounts of what it contains are not consistent with one another. |
| Mechanism as described in the literature | No mechanism has been described for the blend, because the blend has not been studied. The constituents have separate literatures covering fatty-acid transport, hepatic lipid export, insulin signalling and one-carbon metabolism, generated at oral or dietary exposure rather than by injection into subcutaneous fat. | A detergent action. Sodium deoxycholate disrupts cell membranes non-selectively, and the published experiments attribute volume loss to adipocyte lysis rather than to any enzymatic lipolytic pathway. Later work has also described phosphatidylcholine acting on adipocytes through cytokine release and apoptosis over a longer interval. |
| Size of the evidence base | Large at component level and absent at product level. Pooled analyses include 37 randomised trials of L-carnitine, 30 trials of inositol isomers conducted to inform international guidelines, and a meta-analysis of 66 articles on vitamin B12 status. None of those studies used the combined injectable. | Smaller but generated on the intervention itself. Two phase 3 randomised placebo-controlled trials of deoxycholic acid in submental fat, a follow-up of their responders to three years, a systematic review of 25 studies and 3,178 patients at non-submental sites, and a series of rodent and cell experiments dissecting the formulation. |
| Best-characterised finding | Modest pooled reductions in body weight, body mass index and fat mass with oral L-carnitine, and resolution of hepatic steatosis when intravenous choline was given to patients who had become choline-deficient on long-term parenteral nutrition. Both were observed in settings unrelated to local fat reduction. | That deoxycholate rather than phosphatidylcholine produces the cell death. In a randomised double-blind submental trial the two arms did not differ, and in cultured adipocytes neither agent induced an enzymatic lipolytic pathway while the detergent reduced viability at low concentrations. |
| Human data | Present for the individual constituents and almost entirely oral or dietary: randomised trials and meta-analyses of carnitine, inositol, choline and vitamin B12, plus observational cohorts. No human trial of the injected mixture exists, and no human study has injected any constituent subcutaneously for local fat reduction. | Substantial for deoxycholic acid, with phase 3 randomised placebo-controlled trials using photographic and patient-reported endpoints and a follow-up of responders to three years. For compounded phosphatidylcholine with deoxycholate the human data are smaller and older, and for the branded product there are none. |
| Safety signals reported | None specific to the blend, since it has not been studied. Component trials reported gastrointestinal complaints with inositol isomers and found no significant difference between oral, sublingual and intramuscular vitamin B12 in serum cobalamin or homocysteine response. | Documented and in places serious. Injection-site swelling and induration, marginal mandibular nerve paresis, ulceration and necrosis have been reported after deoxycholic acid, and compounded injection lipolysis has been associated with fibrosis, heterotopic ossification and atypical infection. A rat study of intrafascicular exposure documented demyelinating nerve injury. |
| Regulatory status | Not an authorised medicine in any jurisdiction. The mixture is compounded, and the individual constituents are regulated as nutrients or, for vitamin B12, as a treatment for deficiency, neither of which is an authorisation for injected fat reduction. | Deoxycholic acid is an approved injectable for submental fat in adults. Compounded phosphatidylcholine with deoxycholate is not approved for that use, and no approval covers the branded product or any non-submental site. |
| Basis of most marketing claims | Transfer of oral and dietary findings about single nutrients to an injected multi-ingredient preparation, a step the underlying trials do not support and which the research entry in this library identifies as the central gap. | Transfer of results from the approved deoxycholic acid trials to a differently described and unstudied branded formulation, and to body regions that the registrational trials did not cover. |
And what it does not.
Nothing in the published record compares these two products, and the reason differs on each side. The lipotropic blend has never been injected in a study of any kind; its constituents were investigated as oral supplements or dietary exposures, in populations selected for liver disease, polycystic ovary syndrome, pregnancy or nutrient deficiency, and those results do not carry over to a multi-ingredient injection whose pharmacokinetics and interactions have never been measured. The branded lipolytic has not been studied either, but the class it belongs to has, and that literature is unusually clear about mechanism: the bile salt destroys adipocyte membranes, the phospholipid adds little, and the destruction is not selective for fat. The approved bile-salt product has controlled human trials, which the blend does not, but those trials covered one small anatomical region and reported serious local complications alongside the benefit. A reader looking for evidence that either preparation reduces fat where it is injected will find controlled human data on only one side, none at all for either product as sold, and no published basis for ranking one against the other.
Common questions.
- Has any study injected the methionine, inositol, choline, carnitine and vitamin B12 mixture?
No. Searches of PubMed and Europe PMC returned no trial, case report or mechanistic study of the combined lipotropic injectable. The published evidence for each constituent comes from oral supplementation trials, controlled feeding studies and observational nutrition cohorts. Nothing has measured how the mixture behaves after injection, whether the components interact, or what happens to subcutaneous tissue at the injection site, which is the question a local fat-reduction claim depends on.
- Why does the research describe deoxycholic acid when the branded lipolytic is named differently?
Because the branded formulation does not appear in the indexed literature at all. The research entry in this library states that no peer-reviewed clinical or mechanistic study of it was identified, so the evidence presented for its category is the deoxycholic acid and phosphatidylcholine-deoxycholate literature. Marketed accounts of the branded product are inconsistent, some describing a bile-salt preparation and others a riboflavin-based one, and no independent publication has verified either description or measured what the product contains.
- Did adding phosphatidylcholine improve the results of deoxycholate injections?
Not in the trial that tested the question. A randomised double-blind study in submental fat compared deoxycholate alone with a phosphatidylcholine-deoxycholate mixture and found no notable difference in photographic improvement, physical examination, adverse-event profile or participants' own assessments, and both arms produced only modest change. Laboratory work pointed the same way: in cultured adipocytes the loss of viability tracked the detergent, and neither compound induced an enzymatic lipolytic pathway.
- Does the L-carnitine evidence support injecting it into fat?
The pooled trials do not address that use. A meta-analysis of 37 randomised trials and a later umbrella analysis of eight meta-analyses reported small reductions in body weight, body mass index and waist circumference, with wide variation across the underlying studies. Those trials gave carnitine by mouth and measured whole-body outcomes. No published study has injected carnitine subcutaneously to reduce fat at the injection site, so the local effect remains unmeasured.
- What complications have been reported after injection lipolysis?
The reported profile includes injection-site swelling and induration, marginal mandibular nerve paresis, and skin ulceration and necrosis. Compounded phosphatidylcholine with deoxycholate has additionally been linked in case reports to abdominal fibrosis mimicking desmoid fibromatosis, heterotopic ossification of the masseter muscle, and atypical infection after facial injection. In animal work, repeated injection produced muscle degeneration, fibrosis and myelin degeneration at the site, and intrafascicular exposure produced demyelinating nerve injury.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.